- Home
- Publications
- Publication Search
- Publication Details
Title
Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics
Authors
Keywords
-
Journal
CLINICAL PHARMACOKINETICS
Volume 57, Issue 8, Pages 911-928
Publisher
Springer Nature
Online
2018-01-20
DOI
10.1007/s40262-017-0624-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EASL Recommendations on Treatment of Hepatitis C 2016
- (2017) JOURNAL OF HEPATOLOGY
- A Review of Daclatasvir Drug–Drug Interactions
- (2016) Tushar Garimella et al. ADVANCES IN THERAPY
- Assessment of Drug-Drug Interactions between Daclatasvir and Methadone or Buprenorphine-Naloxone
- (2015) T. Garimella et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment
- (2015) Tushar Garimella et al. ANTIVIRAL THERAPY
- An Open-Label Investigation into Drug–Drug Interactions Between Multiple Doses of Daclatasvir and Single-Dose Cyclosporine or Tacrolimus in Healthy Subjects
- (2015) Marc Bifano et al. CLINICAL DRUG INVESTIGATION
- Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug–Drug Interactions
- (2015) Timothy Eley et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir
- (2015) Brian J. Kirby et al. CLINICAL PHARMACOKINETICS
- Organic Anion Transporting Polypeptide-Mediated Transport of, and Inhibition by, Asunaprevir, an Inhibitor of Hepatitis C Virus NS3 Protease
- (2015) T Eley et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Pharmacokinetics of Daclatasvir and Asunaprevir Administered in Combination in Studies in Healthy Subjects and Patients Infected with Hepatitis C Virus
- (2014) Timothy Eley et al. CLINICAL DRUG INVESTIGATION
- Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
- (2014) Hiromitsu Kumada et al. HEPATOLOGY
- Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
- (2013) Marc Bifano et al. ANTIVIRAL THERAPY
- Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate
- (2013) Marc Bifano et al. ANTIVIRAL THERAPY
- Novel therapies for hepatitis C — one pill fits all?
- (2013) Michael P. Manns et al. NATURE REVIEWS DRUG DISCOVERY
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
- (2010) Min Gao et al. NATURE
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
- (2009) David L. Thomas et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started